112 parallel-computing-numerical-methods-"Simons-Foundation" positions at Nature Careers in United Kingdom
Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
excited to dive into the world of computational genomics? Join our team to work at the interface of cutting-edge wet lab techniques and data-driven discovery. This position is ideal for a candidate with a
-
August 2025 Background To create and contribute to the creation of knowledge by undertaking advanced analysis and validation experiments within the MRC BioFlare research programme: Although outcomes in RA
-
Supervise students on research-related work and provide guidance to PhD students where appropriate to the discipline Contribute to developing new computational models, techniques and methods Undertake
-
within an established research programme and/or specific research project. This project involves addressing the issue of triboelectric energy nanogenerators to power ingestible devices. Ingestible devices
-
to the creation of knowledge by undertaking a specified range of activities within an established research programme and/or specific research project. Our international group of highly motivated and
-
Contribute to developing new models, techniques and methods as appropriate Undertake management/administration arising from research Contribute to public engagement activities of manifest benefit to
-
students on research related work and provide guidance to PhD students where appropriate to the discipline Contribute to developing new models, techniques and methods as appropriate Undertake management
-
, techniques or methods and ability to contribute to developing new ones Ability to assess resource requirements and use resources effectively Contribute to the planning and organising of the research programme
-
experienced biophysicist/computational chemist to join our liquid phase electron microscopy team to develop molecular dynamics simulations of cryo-EM and LPEM maps to inform our experimental observations, as
-
oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor prognosis, and this clinic